In the Green: Akero Therapeutics Inc (AKRO) Closes at 51.82, Up/Down -0.12 from Previous Day

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

In the latest session, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $51.82 down -0.12% from its previous closing price of $51.88. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 0.88 million shares were traded. AKRO stock price reached its highest trading level at $52.55 during the session, while it also had its lowest trading level at $51.25.

Ratios:

For a deeper understanding of Akero Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.80 and its Current Ratio is at 16.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.

On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.

On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’25 when Yale Catriona sold 10,000 shares for $52.95 per share. The transaction valued at 529,467 led to the insider holds 91,488 shares of the business.

Cheng Andrew sold 30,000 shares of AKRO for $1,534,895 on Jul 10 ’25. The President and CEO now owns 520,757 shares after completing the transaction at $51.16 per share. On Jul 07 ’25, another insider, Rolph Timothy, who serves as the Chief Scientific Officer of the company, sold 12,500 shares for $51.09 each. As a result, the insider received 638,661 and left with 167,124 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 4130966016 and an Enterprise Value of 3480896512.

Stock Price History:

The Beta on a monthly basis for AKRO is -0.28, which has changed by 0.8298023 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.34. The 50-Day Moving Average of the stock is 2.34%, while the 200-Day Moving Average is calculated to be 28.40%.

Shares Statistics:

For the past three months, AKRO has traded an average of 1.60M shares per day and 890860 over the past ten days. A total of 79.67M shares are outstanding, with a floating share count of 71.78M. Insiders hold about 9.95% of the company’s shares, while institutions hold 101.98% stake in the company. Shares short for AKRO as of 1751241600 were 9059720 with a Short Ratio of 5.66, compared to 1748563200 on 6914326. Therefore, it implies a Short% of Shares Outstanding of 9059720 and a Short% of Float of 11.690000000000001.